ERBB2 and metastatic neoplasm: However, this paradigm has been recently questioned with the established role of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in treating hormone-receptor positive/HER-2 negative (HR+/HER2-) metastatic disease [10–13], in addition to other emerging innovative therapies such as antibody-drug conjugates (ADCs).